Bull Harbor Capital LLC Invests $720,000 in Tenet Healthcare Corporation $THC

Bull Harbor Capital LLC purchased a new stake in shares of Tenet Healthcare Corporation (NYSE:THC) in the 1st quarter, Holdings Channel reports. The institutional investor purchased 3,815 shares of the company’s stock, valued at approximately $720,000.

Other institutional investors and hedge funds have also modified their holdings of the company. Swedbank AB grew its position in Tenet Healthcare by 14.7% during the 4th quarter. Swedbank AB now owns 146,133 shares of the company’s stock worth $29,040,000 after purchasing an additional 18,750 shares during the last quarter. Jackson Creek Investment Advisors LLC grew its position in shares of Tenet Healthcare by 235.6% during the 4th quarter. Jackson Creek Investment Advisors LLC now owns 9,032 shares of the company’s stock valued at $1,795,000 after buying an additional 6,341 shares during the last quarter. Hsbc Holdings PLC increased its stake in Tenet Healthcare by 3,478.7% in the 4th quarter. Hsbc Holdings PLC now owns 266,400 shares of the company’s stock worth $53,269,000 after purchasing an additional 258,956 shares in the last quarter. Louisiana State Employees Retirement System acquired a new stake in shares of Tenet Healthcare in the 1st quarter valued at $4,812,000. Finally, Brandywine Global Investment Management LLC increased its holdings in shares of Tenet Healthcare by 20.5% during the 4th quarter. Brandywine Global Investment Management LLC now owns 126,248 shares of the company’s stock worth $25,088,000 after purchasing an additional 21,435 shares during the period. Institutional investors own 95.44% of the company’s stock.

Tenet Healthcare Stock Down 1.9%

Shares of THC opened at $252.80 on Friday. The company has a quick ratio of 1.35, a current ratio of 1.41 and a debt-to-equity ratio of 2.00. The stock’s 50-day moving average price is $190.49 and its 200-day moving average price is $198.96. Tenet Healthcare Corporation has a 52 week low of $156.71 and a 52 week high of $262.68. The company has a market capitalization of $21.78 billion, a price-to-earnings ratio of 9.75, a PEG ratio of 0.98 and a beta of 1.27.

Tenet Healthcare (NYSE:THC) last announced its quarterly earnings results on Thursday, July 23rd. The company reported $6.12 earnings per share for the quarter, beating analysts’ consensus estimates of $4.26 by $1.86. Tenet Healthcare had a net margin of 10.27% and a return on equity of 26.76%. The business had revenue of $6.04 billion during the quarter, compared to analysts’ expectations of $5.43 billion. During the same period last year, the business earned $4.02 earnings per share. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. Tenet Healthcare has set its FY 2026 guidance at 20.300-21.690 EPS. On average, sell-side analysts predict that Tenet Healthcare Corporation will post 21.09 EPS for the current year.

Insider Transactions at Tenet Healthcare

In other Tenet Healthcare news, Director Christopher S. Lynch sold 3,837 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $243.44, for a total value of $934,079.28. Following the completion of the sale, the director owned 9,568 shares of the company’s stock, valued at $2,329,233.92. This trade represents a 28.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paola M. Arbour sold 10,878 shares of the business’s stock in a transaction that occurred on Monday, July 27th. The stock was sold at an average price of $243.90, for a total value of $2,653,144.20. Following the transaction, the executive vice president owned 18,413 shares of the company’s stock, valued at approximately $4,490,930.70. This represents a 37.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 23,353 shares of company stock worth $5,103,217 over the last 90 days. Company insiders own 0.97% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on THC. UBS Group increased their price target on Tenet Healthcare from $288.00 to $308.00 and gave the stock a “buy” rating in a report on Monday. Piper Sandler set a $308.00 price objective on shares of Tenet Healthcare in a report on Monday. Robert W. Baird lifted their price target on Tenet Healthcare from $210.00 to $280.00 and gave the company a “neutral” rating in a research note on Tuesday. Wells Fargo & Company boosted their price objective on Tenet Healthcare from $213.00 to $231.00 and gave the company an “overweight” rating in a research note on Monday, July 13th. Finally, KeyCorp cut their price objective on Tenet Healthcare from $250.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Seventeen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, Tenet Healthcare currently has a consensus rating of “Moderate Buy” and a consensus target price of $268.50.

More Tenet Healthcare News

Here are the key news stories impacting Tenet Healthcare this week:

• Positive Sentiment: Analysts raised their price targets: Truist lifted its target to $290, while Guggenheim increased its target to $283 and Robert W. Baird raised its target to $280. The revisions reflect growing confidence in Tenet’s earnings outlook and imply additional upside from recent trading levels. Truist raises Tenet Healthcare price target Baird analyst comments on Tenet Healthcare Guggenheim analyst comments on Tenet Healthcare
• Positive Sentiment: Growth and momentum remain key attractions: Zacks highlighted Tenet’s above-average financial growth, strong momentum characteristics and potential appeal to growth-focused investors. These reports may support continued retail and quantitative-investor interest in THC. Three reasons growth investors may like Tenet Healthcare Tenet Healthcare momentum analysis
• Positive Sentiment: Fundamental performance supports the bullish case: Tenet’s latest quarterly results exceeded estimates, with EPS of $6.12 versus a $4.26 consensus and revenue of $6.04 billion versus $5.43 billion expected. The company also raised its 2026 outlook, strengthening the investment case behind the recent rally.
• Neutral Sentiment: Investor attention is elevated: Zacks reported increased user interest in Tenet and noted that the stock recently reached a 52-week high. However, the coverage is largely informational and does not represent a new company announcement or change in fundamentals. Zacks analysis of investor attention on Tenet Healthcare
• Negative Sentiment: Insider selling creates a modest overhang: EVP Paola Arbour sold 10,878 shares for approximately $2.65 million, while Director Christopher Lynch sold 3,837 shares worth about $934,000. Both transactions significantly reduced their holdings, although the sales may reflect personal financial planning rather than a negative view of Tenet’s prospects.

Tenet Healthcare Company Profile

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.